---
document_datetime: 2024-11-20 10:50:41
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elfabrio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: elfabrio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.479676
conversion_datetime: 2026-01-20 20:20:21.202785
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Elfabrio

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                           |
|----------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11049 /202311  | Periodic Safety Update EU Single assessment - pegunigalsidase alfa                                    | 13/06/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                                 |
| II/0004/G            | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished | 23/05/2024                          |                                             | SmPC, Labelling and PL           | The SmPC sections 2, 6.5, 6.6 and 8 have been updated to include the addition of new presentations of 1, 2 and 5 vials of 2.5 ml presentation of Elfabrio 2 mg/ml concentrate for |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products                                            |            |     | solution for infusion (EU/1/23/1724/004-006) The Labelling and PL have been updated accordingly.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------|
| II/0002   | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/05/2024 | n/a |                                                                                                    |
| IB/0001/G | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 19/06/2023 | n/a |                                                                                                    |